Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus CAMBIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus CAMBIA.
ANSAID vs CAMBIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating inflammation, pain, and fever.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
50 mg orally once daily as needed for acute migraine, maximum 1 packet (50 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life of diclofenac (active moiety) is approximately 1.9-2.1 hours. The clinical context: short half-life supports twice-daily dosing for acute pain.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Approximately 50% of a dose is excreted in urine primarily as metabolites and conjugates, with less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 40%.
Category C
Category C
NSAID
NSAID